Targets to Therapies: Mitochondrial Target Validation
Funds research to validate mitochondrial targets in Parkinson’s disease by supporting mechanistic studies, human relevance, and tool development for therapeutic advancement.
Funder: Michael J. Fox Foundation for Parkinson's Research
Due Dates: Rolling (pre-proposals accepted year-round)
Funding Amounts: Typical awards up to $500,000 total costs for up to 2 years; budgets must be justified and aligned with project scope.
Summary: Supports research to validate mitochondrial targets relevant to Parkinson’s disease, focusing on mechanistic studies, human relevance, and tools for therapeutic development.
Key Information: Pre-proposal submission is required for invitation to full proposal; open to global academic and for-profit researchers.
Description
This program, part of the Michael J. Fox Foundation's Targets to Therapies Initiative, funds research to build a robust evidence base for mitochondrial targets with potential relevance to Parkinson’s disease (PD). Projects should clarify the human relevance of mitochondrial targets, define mechanisms in PD contexts, establish target engagement, and develop tools or assays that enable further research and therapeutic development. The initiative emphasizes translational, reproducible data that move targets closer to therapeutic decision points and specifically seeks to address known gaps in the field, such as human modulation and biomarker linkage.
